Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SAIC +7.7%, GME +4.6% (also amends convertible note exchange; fixes share issuance and adds $358.4 mln cash settlement)
Other news:
- GDEV +6.3% (launches $20 mln self tender offer at $11.03/share)
- IPX +4.7% (secures second U.S. army task order to accelerate industrial-scale American titanium production)
- OBX +4.3% (files for 29,164,045 share common stock offering by selling shareholders)
- HCM +2.6% (says SANOVO Phase 3 trial met PFS endpoint for ORPATHYS plus AstraZeneca's TAGRISSO in first-line EGFR-mutant NSCLC)
- RNGR +2.6% (to acquire STEP Energy Services' U.S. coiled tubing assets)
- JMIA +2.3% (files for 2,717,389 share ADS offering by selling securityholders)
- BMRN +2.3% (settles global patent disputes with Ascendis; royalties set on Yuviwel sales)
- TMQ +2% (executes definitive agreements with the US Dept of War in connection with previously announced strategic equity investment)
- GILT +2% (announces $100 mln private placement of 3.75% convertible notes due 2031 at 60% conversion premium)
- PTCT +2% (FDA approval of hepcidin mimetic peptide MIMRYLO(TM) (rusfertide) for polycythemia vera)
- KRP +1.9% (files for 9,500,000 common unit offering by selling unitholders)
- SLB +1.5% (to buy Kelvion from Apollo Funds (APO) for $4.1 bln - SLB to host call at 10 a.m. ET; expects the transaction to be accretive to both earnings per share and free cash flow per share in the first 12 months)
- MTLS +1.3% (announces their share buyback program will restart with effect from August 31)
- DKS +1.2% (discloses several insider purchases)
- NWFL +1.1% (adopts new stock repurchase program for up to 550,000 shares)
- TAK +1.1% (wins FDA approval for MIMRYLO in adults with polycythemia vera)
- BBIO +1.1% (presents new acoramidis ATTR-CM data showing structural and hospitalization benefit)